Treatment of Relapsed or Refractory AML with Intermediate-dose Arabinosylcytosine (Ara-C): Confirmation of the Importance of Ara-C Triphosphate Formation in Mediating Response to Ara-C
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 10 (sup1) , 115-121
- https://doi.org/10.3109/10428199309149123
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Cytarabine and neurologic toxicity.Journal of Clinical Oncology, 1991
- Modulation of arabinosylcytosine metabolism by arabinosyl-2- fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapyBlood, 1989
- Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemiaThe American Journal of Medicine, 1986
- Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinosideBritish Journal of Haematology, 1984
- High-dose cytosine arabinoside therapy for refractory leukemiaBlood, 1983
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Cytarabine for Acute Leukemia in AdultsArchives of internal medicine (1960), 1974